Samsung Biologics Signs 279.6 Billion Won Contract with European Pharmaceutical Company
Samsung Biologics has signed a large-scale contract manufacturing agreement for pharmaceuticals with a European pharmaceutical company.
Panoramic view of Samsung Biologics Plant 4 in Songdo, Incheon. Samsung Biologics
View original imageOn March 13, Samsung Biologics announced through a public disclosure that it had signed a contract manufacturing agreement for pharmaceuticals worth 279.6 billion won with a European pharmaceutical company. This amount is equivalent to 6.15% of its consolidated revenue of 4.5473 trillion won in 2024.
The contract period began on July 31, 2025, and is scheduled to end on March 13, 2032. However, the termination date may be subject to change based on mutual agreement between the two parties.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The specific name of the European pharmaceutical company, which is the counterparty to the contract, was not disclosed due to business confidentiality reasons.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.